OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema.

Trial Profile

OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 13 Aug 2016

At a glance

  • Drugs Avoralstat (Primary)
  • Indications Hereditary angioedema
  • Focus Therapeutic Use
  • Acronyms OPuS-2
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 15 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 08 Feb 2016 Results published in a BioCryst media release.
    • 08 Feb 2016 Primary endpoint 'The mean acute angioedema attack rate' has not been met, according to a BioCryst media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top